• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Opaleye Management Inc. bought $5,487,000 worth of shares (2,325,000 units at $2.36) (SEC Form 4)

    5/28/25 4:05:23 PM ET
    $CDXS
    Major Chemicals
    Industrials
    Get the next $CDXS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Opaleye Management Inc.

    (Last) (First) (Middle)
    ONE BOSTON PLACE,
    26TH FLOOR

    (Street)
    BOSTON MA 02108

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CODEXIS, INC. [ CDXS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/23/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.001 per share 05/23/2025 P 2,320,000 A $2.36 11,995,000 I By Opaleye, L.P.(1)(3)
    Common Stock, par value $0.001 per share 05/28/2025 P 5,000 A $2.36 12,000,000 I By Opaleye, L.P.(1)(3)
    Common Stock, par value $0.001 per share 250,000 I By Managed Account(2)(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
    2. Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
    3. Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    Opaleye Management Inc., By: /s/ James Silverman, President 05/28/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CDXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDXS

    DatePrice TargetRatingAnalyst
    8/19/2024Buy → Hold
    The Benchmark Company
    6/3/2024$5.00Buy
    Jefferies
    5/30/2024$11.00Overweight
    Cantor Fitzgerald
    2/29/2024Hold → Buy
    The Benchmark Company
    11/7/2023Buy → Hold
    The Benchmark Company
    8/7/2023$21.00 → $4.00Outperform → Market Perform
    TD Cowen
    5/9/2023Buy → Neutral
    H.C. Wainwright
    3/31/2022$35.00Overweight
    Piper Sandler
    More analyst ratings

    $CDXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

       Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases Management to host conference call today at 8 am Eastern Time to discuss data REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis' presentations showcased its proprietary ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demon

      5/22/25 7:00:00 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis to Participate in Jefferies Global Healthcare Conference

      REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 3-5, 2025, in New York, New York. Management will participate in a fireside chat on Wednesday, June 4, 2025, at 3:10 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company's website, https://ir.codexis.com. A replay will be archived for 90 days following the event. About Codexis Codexis is a leading provider of enzymatic solutions for efficient and scalable therape

      5/21/25 4:05:00 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Reports First Quarter 2025 Financial Results

      Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading CDMO collaborators REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. "Codexis finished the first quarter with $60 million in cash, which remains on track to fund the company through cash flo

      5/14/25 4:05:00 PM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. bought $560,009 worth of shares (250,000 units at $2.24) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      6/16/25 4:59:00 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Large owner Opaleye Management Inc. bought $5,487,000 worth of shares (2,325,000 units at $2.36) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      5/28/25 4:05:23 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Large owner Opaleye Management Inc. bought $104,096 worth of shares (45,000 units at $2.31) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      5/2/25 4:05:14 PM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Codexis downgraded by The Benchmark Company

      The Benchmark Company downgraded Codexis from Buy to Hold

      8/19/24 8:50:44 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Jefferies resumed coverage on Codexis with a new price target

      Jefferies resumed coverage of Codexis with a rating of Buy and set a new price target of $5.00

      6/3/24 8:45:11 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Cantor Fitzgerald initiated coverage on Codexis with a new price target

      Cantor Fitzgerald initiated coverage of Codexis with a rating of Overweight and set a new price target of $11.00

      5/30/24 7:33:26 AM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    SEC Filings

    See more
    • Codexis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CODEXIS, INC. (0001200375) (Filer)

      6/11/25 4:01:18 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • SEC Form 10-Q filed by Codexis Inc.

      10-Q - CODEXIS, INC. (0001200375) (Filer)

      5/14/25 4:17:18 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - CODEXIS, INC. (0001200375) (Filer)

      5/14/25 4:09:05 PM ET
      $CDXS
      Major Chemicals
      Industrials